119th Congress
H.R. 4780
USTRx Act
- Introduced
- In committee
- Passed House
- Passed Senate
- To President
- Became law
- Sponsor
- Jodey C. Arrington(R-TX)
- Introduced
- Jul 29, 2025
- Policy area
- Foreign Trade and International Finance
- Committees
- House Committee on Ways and Means
- Official text
- Introduced in House · Congress.gov page
Cosponsors (8)
Original cosponsors (4)
- Charles J. "Chuck" Fleischmann (R-TN)
- Claudia Tenney (R-NY)
- Gregory F. Murphy (R-NC)
- Vern Buchanan (R-FL)
Added later (4)
- Carol D. Miller (R-WV) · Aug 5, 2025
- James R. Baird (R-IN) · Mar 27, 2026
- Nathaniel Moran (R-TX) · Apr 20, 2026
- W. Gregory Steube (R-FL) · Jul 21, 2026
Summary
Summary by the Congressional Research Service· describes the “Introduced in House” version
Use Sovereignty To reduce Rx Act or the USTRx Act
This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers.
The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.
The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.
Roll-call votes
No recorded votes on this bill.
Actions
- Jul 29, 2025 · House
Referred to the House Committee on Ways and Means. - Jul 29, 2025
Introduced in House